Shuttle Pharmaceuticals Holdings, Inc. (NasdaqCM: SHPH)
Health Care · Biotechnology · US
$3.91
+3.99% today · -88.7% 1Y
Shuttle Pharmaceuticals Holdings, Inc. (NasdaqCM: SHPH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.20M and employs 2 people.
Over the last twelve months the share price has lost 88.7%, trading between 2.58 and 55.90.
Tweenvest scores Shuttle Pharmaceuticals Holdings, Inc. across four factors: quality 20/100. Its strongest factor is quality.
SHPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.20M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -38.73
- Dividend yield
- —
- Beta (5Y)
- 1.22
- 52-week high
- $55.90
- 52-week low
- $2.58
- Avg volume (3M)
- —
- Shares outstanding
- 585.13K
- Employees
- 2
- Next earnings
- —
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
- ISIN
- US8256935003
- Founded
- 2012
- Listed since
- Aug 31, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.